Home / Initiative / Covaxin
Initiative

Covaxin

Asked 2 times across 2 UPSC exams, peaking in 2022.
2
PYQs
2
Exams
1
Years active
2022–2022
Span
2022
Peak
2/2
Answers
📅 Full chronological timeline →

Key insights

  • Most tested in CSE — 1 of 2 PYQs
  • Most asked in 2022
  • Recurs across 1 years (2022–2022)

How it travelled across exams

First appearance in each exam — the same idea, reframed.
CSE 2022 GEO 2022

How the concept evolved

222
Rising — more than half its appearances (2 of 2) are since 2016.

Related concepts

Ideas UPSC tests alongside this one — keep exploring.

Sample questions

You've seen the pattern — here are a few of the actual PYQs.
CSE2022

In the context of vaccines manufactured to prevent COVID-19 pandemic, consider the following statements

  1. The Serum Institute of India produced COVID-19 vaccine named Covishield using mRNA platform
  2. Sputnik V vaccine is manufactured using vector based platform
  3. COVAXIN is an inactivated pathogen based vaccine

Which of the statements given above is/are correct?

  1. A 1 and 2 only
  2. B 2 and 3 only ✓
  3. C 1 and 3 only
  4. D 1, 2 and 3
✓ Correct answer: (B)
Science & Technology › Biotech & Genetics
GEO2022
Covaxin, a COVID-19 vaccine manufactured in India, is
  1. A a live attenuated virus vaccine
  2. B an inactivated whole virus vaccine ✓
  3. C a messenger RNA vaccine
  4. D a protein subunit vaccine
✓ Correct answer: (B)
Science & Technology › Biology & Health

Study how UPSC repeats — not just the papers

₹199 / 1 year · Founding Member

Full access unlocks the three things no PYQ PDF gives you:
① Cross-exam learning — see the same idea recur across CSE, CAPF, CDS and NDA.
② Topic evolution — how each idea is framed, year by year.
③ Question intelligence — every PYQ + answer, linked to related concepts and similar questions.

e.g. Round Table Conference: CDS 2017 → CSE 2017 → … → CAPF 2024

15 days free, no card required — then ₹199 for 1 year.

Start your 15-day free trial →
CrispUPSC · YouTube · Telegram · About · What’s New · invite-only beta
💬 Feedback

Send feedback